Pipeline

Imsidolimab (ANB019):Anti-IL-36R DEVELOPMENT STAGE & ANTICIPATED MILESTONES THERAPEUTIC INDICATION COMMERCIAL RIGHTS ANTIBODY PROGRAM DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 Phase 1 DataPresented atEAACI 2018 GALLOP: Phase 2 Data Presented AtEADV Congress on October 2nd 2021 Phase 3 InitiatedQ3 2021 ACORN: Topline Data Anticipated H1 2022 HARP: Topline Data Anticipated H2 2022 Generalized PustularPsoriasis Acne Vulgaris JEMPERLI (dostarlimab):Anti-PD-1 Antagonist FIRST: Ongoing US BLA and EU MAAApproved April 2021 US BLA ApprovedAugust 2021 OPAL: Ongoing dMMR Pan-Tumor Ovarian Cancer dMMR Endometrial Cancer PERLA: Ongoing NSCLC Cobolimab (GSK4069889): Anti-TIM-3 Antagonist COSTAR: Dostarlimab Combination Trial Ongoing GSK4074386: Anti-LAG-3 Antagonist CITRINO: Dostarlimab Combination Trial Ongoing Immuno-Oncology TSR-075: Anti-PD-1/ LAG-3 Bispecific IND-Enabling Studies Ongoing Immuno-Oncology CC-90006: Anti-PD-1 Agonist Ongoing Psoriasis Undisclosed Ongoing Inflammation ANB032: Anti-BTLA Modulator Inflammatory Diseases NSCLC HidradenitisSuppurativa Topline Phase 1Data AnticipatedH1 2022 Rosnilimab (ANB030):Anti-PD-1 Agonist Alopecia Areata Phase 1 Top-LineData AnticipatedQ4 2021 Phase 2 Initiation Anticipated During Upcoming Few Months